As of today, our current ongoing activities within the Institute have been further reduced, or even completely stopped in order to: facilitate the work of hospitals and care centers by...
A Covid-19 learning By Nathalie Garçon, CEO/CSO BIOASTER The current crisis reminds us today of the absolute and universal need to prepare in advance for such epidemics, which no...
We are going through a major and unprecedented crisis, which involves drastically rethinking our lifestyles and work to slow down the epidemic, which is now ubiquitous, allow our health system...
@BIOASTER receives $885K grant from the Bill & Melinda Gates Foundation @gatesfoundation to develop #Onchocerciasis advanced rapid #diagnostic with @mologic Ltd. BIOASTER, today announced it has received a grant in...
Have a look to our brand new video online on EXPERTISES @BIOASTER’s series about SMART OMICS: Video SMART OMICS The BIOASTER omics Hub team presents SMART OMICS concept. Omics technologies...
APPLICATION NOTE from the OMICs HUB about inter-individual heterogeneity in clinical metabolomics studies: Assessment of inter-individual NMR/MS metabolic signatures variability in plasma of a heterogeneous group of healthy volunteers –...
BioFilm Pharma and BIOASTER announced the signature of a research contract to address the challenge of antibiotic resistance. This collaboration will lead to the deciphering of the mode of action...
#OmicsTechnologies are today in the heart of early research in #microbiology and #InfectiousDiseases. To leverage these #technologies in applied research, we need to develop new solutions corresponding to industrial processes...
Kaleido Biosciences to collaborate with BIOASTER and MetaGenoPolis to investigate the health potential of a novel class of therapies targeting the microbiome. Kaleido Biosciences, a U.S.-based clinical-stage healthcare company, and...
A new publication about #Chagas disease has been released on November in Journal of Medicinal Chemistry. Entitled “Chagas Disease Drug Discovery: multiparametric Lead Optimization against Trypanosoma cruzi in AcylAminoBenzothiazole Series”....
By continuing browsing this website, you accept the use of cookies or other tracers for statistics of visits to optimize the functionality of the site, and or privacy policy. AcceptRejectRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
